丁丙诺啡与抗逆转录病毒药物的相互作用：核苷（酸）逆转录酶抑制剂（NRTI）地达诺辛、拉米夫定和替诺福韦。
Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
机构信息
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.
出版信息
Am J Addict. 2010 Jan-Feb;19(1):17-29. doi: 10.1111/j.1521-0391.2009.00004.x.
Abstract
To improve outcomes among injection drug users with HIV and/or chronic hepatitis B, it is important to identify drug interactions between antiretroviral and opiate therapies. We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmacokinetic nor pharmacodynamic interaction.
摘要
为了改善感染 HIV 和/或慢性乙型肝炎的注射吸毒者的治疗效果，识别抗逆转录病毒和阿片类药物治疗之间的药物相互作用非常重要。我们报告了一项旨在研究丁丙诺啡与核苷（酸）逆转录酶抑制剂（NRTI）地达诺辛（ddI）、拉米夫定（3TC）和替诺福韦（TDF）之间相互作用的研究结果。接受丁丙诺啡/纳洛酮维持治疗、HIV 阴性的阿片类药物依赖志愿者（n=27）参与了两个 24 小时的疗程，以确定：（1）丁丙诺啡单独的药代动力学；（2）丁丙诺啡和 ddI、3TC 或 TDF 联合应用的药代动力学。在丁丙诺啡/纳洛酮维持治疗的研究参与者中，ddI、3TC 或 TDF 给药后丁丙诺啡的药代动力学没有明显变化。丁丙诺啡对 NRTI 浓度没有显著影响。丁丙诺啡与 ddI、3TC 或 TDF 同时使用既不会产生明显的药代动力学相互作用，也不会产生药效学相互作用。
相似文献
1
Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.丁丙诺啡与抗逆转录病毒药物的相互作用：核苷（酸）逆转录酶抑制剂（NRTI）地达诺辛、拉米夫定和替诺福韦。
Am J Addict. 2010 Jan-Feb;19(1):17-29. doi: 10.1111/j.1521-0391.2009.00004.x.
2
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.接受富马酸替诺福韦二吡呋酯（TDF）的人类免疫缺陷病毒感染患者的药代动力学初步研究：TDF与阿巴卡韦、拉米夫定或洛匹那韦-利托那韦之间的全身和细胞内相互作用研究
Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.
3
[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].[核苷/核苷酸类似物组合（替诺福韦+拉米夫定、去羟肌苷+拉米夫定和替诺福韦+去羟肌苷）对HIV感染且病毒持续抑制患者的免疫效果]
Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. doi: 10.1157/13091779.
4
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.接受三联核苷治疗方案患者中替诺福韦二磷酸酯、卡波韦三磷酸酯和拉米夫定三磷酸酯的细胞内药代动力学。
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11. doi: 10.1097/01.qai.0000167155.44980.e8.
5
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.在感染 HIV-1 的患者中同时给予替诺福韦酯和地达诺新时细胞内核苷酸水平。
Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.
6
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.在法国国家艾滋病研究机构阿基坦队列中，基于HIV-1核苷/核苷酸逆转录酶抑制剂且包含替诺福韦酯的治疗方案的病毒学应答情况。
J Clin Virol. 2006 Jun;36(2):95-9. doi: 10.1016/j.jcv.2006.02.002. Epub 2006 Mar 23.
7
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.替诺福韦联合去羟肌苷作为HIV感染者的核苷类逆转录酶抑制剂主干治疗方案。
Curr Med Chem. 2006;13(23):2789-93. doi: 10.2174/092986706778521931.
8
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.富马酸替诺福韦二吡呋酯与去羟肌苷之间的药物相互作用及药物与食物相互作用。
J Clin Pharmacol. 2005 Dec;45(12):1360-7. doi: 10.1177/0091270005281351.
9
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.尽管病毒载量检测不到，但接受去羟肌苷和替诺福韦治疗方案的患者出现意外的CD4细胞计数下降。
AIDS. 2004 Feb 20;18(3):459-63. doi: 10.1097/00002030-200402200-00012.
10
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.接受去羟肌苷/替诺福韦/依非韦伦治疗的HIV-1感染受试者的早期病毒学失败：一项随机试验的12周结果
AIDS. 2005 Jul 22;19(11):1183-8. doi: 10.1097/01.aids.0000176218.40861.14.
引用本文的文献
1
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.丁丙诺啡群体药代动力学的初步研究结果：HIV对丁丙诺啡生物利用度的潜在影响。
Drug Alcohol Depend. 2022 Dec 1;241:109696. doi: 10.1016/j.drugalcdep.2022.109696. Epub 2022 Nov 11.
2
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.利奥西呱与抗逆转录病毒联合治疗方案在HIV-1感染成人中的药代动力学相互作用。
Pulm Circ. 2019 Apr-Jun;9(2):2045894019848644. doi: 10.1177/2045894019848644.
3
Tailored combination prevention packages and PrEP for young key populations.为年轻重点人群量身定制的综合预防套餐及暴露前预防
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19434. doi: 10.7448/IAS.18.2.19434. eCollection 2015.
4
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.阿片类药物依赖管理的新进展：聚焦于舌下含服丁丙诺啡 - 纳洛酮
Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015.
5
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.HCV 血清阳性状态对阿片类药物依赖者丁丙诺啡药代动力学的影响。
Am J Addict. 2014 Jan-Feb;23(1):34-40. doi: 10.1111/j.1521-0391.2013.12052.x. Epub 2013 Jun 10.
6
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.HIV 或丙型肝炎病毒药物与阿片类激动剂治疗的药物相互作用综述：对临床实践的影响和管理。
Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18.
7
Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.抗反转录病毒治疗的 HIV 感染者中的重要药物相互作用：HIV 与非 HIV 药物之间新的相互作用的更新。
Curr Infect Dis Rep. 2012 Feb;14(1):67-82. doi: 10.1007/s11908-011-0229-1.
8
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.每日一次替诺福韦酯（TDF）为基础的抗逆转录病毒治疗方案在接受阿片类药物治疗的 HIV-1 感染的前注射吸毒者中的疗效、依从性和耐受性：一项 48 周开放性研究的结果。
Eur J Med Res. 2011 Oct 10;16(10):427-36. doi: 10.1186/2047-783x-16-10-427.
9
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.治疗药物监测蛋白酶抑制剂和依非韦伦在有物质相关障碍的 HIV 感染者中的应用。
Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.
10
Gender differences in pharmacokinetics of maintenance dosed buprenorphine.维持剂量丁丙诺啡药代动力学的性别差异。
Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.
本文引用的文献
1
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.在马来西亚市场引入丁丙诺啡/纳洛酮复方制剂后，丁丙诺啡注射液的使用量未减。
Am J Drug Alcohol Abuse. 2009;35(2):68-72. doi: 10.1080/00952990802585406.
2
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.成人HIV感染的抗逆转录病毒治疗：美国国际艾滋病协会专家组2008年建议
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
3
Review article: current antiviral therapy of chronic hepatitis B.综述文章：慢性乙型肝炎的当前抗病毒治疗
Aliment Pharmacol Ther. 2008 Jul;28(2):167-77. doi: 10.1111/j.1365-2036.2008.03731.x. Epub 2008 May 9.
4
Diagnosis and management of hepatitis B virus and HIV coinfection.乙型肝炎病毒与艾滋病毒合并感染的诊断和管理
Top HIV Med. 2007 Nov-Dec;15(5):163-6.
5
Future prospectives for the management of chronic hepatitis B.慢性乙型肝炎管理的未来展望
World J Gastroenterol. 2007 May 14;13(18):2554-67. doi: 10.3748/wjg.v13.i18.2554.
6
Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.
Eur J Clin Microbiol Infect Dis. 2007 May;26(5):367-9. doi: 10.1007/s10096-007-0293-5.
7
Viral hepatitis in HIV infection.HIV感染中的病毒性肝炎
N Engl J Med. 2007 Apr 5;356(14):1445-54. doi: 10.1056/NEJMra065142.
8
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.丁丙诺啡与抗逆转录病毒药物的相互作用。II. 蛋白酶抑制剂奈非那韦、洛匹那韦/利托那韦及利托那韦
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S235-46. doi: 10.1086/508188.
9
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.丁丙诺啡与抗逆转录病毒药物的相互作用。I. 非核苷类逆转录酶抑制剂依非韦伦和地拉韦定。
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S224-34. doi: 10.1086/508187.
10
Antiviral therapy of chronic hepatitis B.慢性乙型肝炎的抗病毒治疗
Antiviral Res. 2006 Sep;71(2-3):206-15. doi: 10.1016/j.antiviral.2006.04.003. Epub 2006 Apr 25.
Zotero 插件